Streetbeat News

PDEX

Pro-Dex, Inc.

Industry

Medical - Instruments & Supplies

Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.

Open

32.93

Mkt cap

104M

Volume

11K

High

33.09

P/E Ratio

16.33

52-wk high

59.60

Low

32.00

Div yield

N/A

52-wk low

16.39

Pro-Dex, Inc. (PDEX) reported Q2 earnings of $0.61 per share, surpassing the Zacks Consensus Estimate of $0.38. This marks a significant increase from $0.14 per share a year ago.

Portfolio Pulse from

January 30, 2025 | 11:30 pm

Pro-Dex, Inc. released its fiscal 2025 second quarter financial results, providing insights into its performance for the period ending December 31, 2024.

Portfolio Pulse from

January 30, 2025 | 9:15 pm

ProDex (PDEX) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings prospects, which could lead to a rise in its stock price.

Portfolio Pulse from

January 28, 2025 | 6:15 pm

ProDex (PDEX) experienced a significant 23% increase in share price with above-average trading volume. However, current earnings estimate revisions do not indicate sustained strength.

Portfolio Pulse from

January 07, 2025 | 1:30 pm

Pro-Dex, Inc. (PDEX) has seen significant stock price growth over the past year, making it an attractive investment option. The company's prospects remain strong, suggesting continued positive performance.

Portfolio Pulse from

January 07, 2025 | 12:00 pm

Several healthcare stocks experienced significant price movements during Friday's intraday session. Notable gainers included Athira Pharma, ChromaDex, and Theriva Biologics, while Lexicon Pharmaceuticals and Myriad Genetics were among the biggest losers.

Portfolio Pulse from Benzinga Insights

November 01, 2024 | 4:36 pm

In Friday's pre-market session, several healthcare stocks experienced significant movements. Envoy Medical, Theriva Biologics, and Athira Pharma saw notable gains, while Lexicon Pharmaceuticals and others faced declines. Earnings reports influenced some stock movements.

Portfolio Pulse from Benzinga Insights

November 01, 2024 | 12:12 pm

Portfolio Pulse from Benzinga Insights

November 01, 2024 | 12:11 pm

Pro-Dex shares rose following the release of their Q1 financial results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 8:47 pm

Pro-Dex (NASDAQ:PDEX) reported strong Q1 2025 earnings, with EPS of $0.75 beating estimates by 158.62% and sales of $14.892M surpassing expectations by 23.07%. This marks a 24.74% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 8:46 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.